Nab-Paclitaxel an Option for Second-Line Advanced NSCLC?

The ABOUND.2L+ trial tested the combination of nab-paclitaxel and CC-486 vs single-agent nab-paclitaxel in patients with advanced NSCLC.

Source: CancerNetwork - November 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news